Q2 2026 saw 60% year-over-year net sales growth to $1.5B and a 146% increase in operating profit, driven by VYVGART's expanded label and strong commercial momentum in MG and CIDP. Cash and financial assets totaled $5.2B at quarter end.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.